ANALYSIS OF TIME INTERVAL BETWEEN BREAST CANCER DIAGNOSIS AND TREATMENT
Keywords:
Breast cancer, chemotherapy, diagnosis, epidemiology, public healthAbstract
Introduction: Breast cancer has a good prognosis when treated early. However, the mortality rate in Brazil is still high. The time interval between radiological suspicion and diagnosis/treatment impacts the survival. Methods: This is a retrospective crosssectional study that assessed patients treated at a reference center, with abnormal breast imaging findings and subsequent confirmation of breast cancer, from January 2011 to June 2015. We reviewed variables related to the dates of the abnormal test result, first mastology appointment, biopsy, surgery, and the start of chemotherapy – when indicated. Time intervals were compared using the Friedman and Kruskal-Wallis tests with the software SPSS® 23.0. Results: We analyzed 65 patients. The median time between the abnormal test result and first mastology appointment was 35 days; between first mastology appointment and biopsy, 31 days; between biopsy and surgery, 85 days; and between surgery and chemotherapy, 137 days. The last two intervals showed significant differences (p<0.001). Discussion: Breast cancer patients had a significant delay until surgery and the start of chemotherapy. Early integration of the multidisciplinary team involved in this process and internal audits are necessary to optimize time intervals.
Downloads
References
Brasil. Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2016 – Incidência de Câncer no Brasil. Brasil: Ministério da Saúde; 2015 [acessado em 29 nov. 2017]. Dísponível em: http://santacasadermatoazulay.com.br/wp-content/uploads/2017/06/estimativa-2016-v11.pdf
Schroeder B, Zhang Y, Stål O, Fornander T, Brufsky A, Sgroi DC, et al. Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer. NPJ Breast Cancer. 2017;3:28. https://doi.org/10.1038/s41523-017-0037-3
Coldman A, Phillips N, Wilson C, Decker K, Chiarelli AM, Brisson J, et al. Pan-Canadian study of mammography screening and mortality from breast cancer. J Natl Cancer Inst. 2014;106(11). https://doi.org/10.1093/jnci/dju261
International Agency for Research on Cancer. Handbooks of Cancer Prevention. Lyon: International Agency for Research on Cancer; 2016. v.15.
Nelson HD, Pappas M, Cantor A, Griffin J, Daeges M, Humphrey L. Harms of breast cancer screening: systematic review to update the 2009 U. S. preventive services task force recommendation. Ann Intern Med. 2016;164:256-67. https://doi.org/10.7326/M15-0970
Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, Looman CWN, van Luijt PA, Fracheboud J, et al. The effect of populationbased mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up. Int J Cancer. 2017;141(4):671-7. https://doi.org/10.1002/ijc.30754
Gagliato DM, Gonzalez-Angulo AM, Lei X, Theriault RL, Giordano SH, Valero V, et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014;32(8):735-44. https://doi.org/10.1200/JCO.2013.49.7693
Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol. 2016;2:322-9. https://doi.org/10.1001/jamaoncol.2015.3856
Raphael MJ, Biagi JJ, Kong W, Mates M, Booth CM, Mackillop WJ. The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2016;160(1):17-28. https://doi.org/10.1007/s10549-016-3960-3
Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet. 1999;353(9159):1119-26.
Vandergrift JL, Niland JC, Theriault RL, Edge SB, Wong YN, Loftus LS, et al. Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst. 2013;105(2):104-12. https://doi.org/10.1093/jnci/djs506
Sickles EA, D’Orsi CJ, Bassett L. ACR BI-RADS® Mammography. In: ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology; 2013.
Mendelson EB, Böhm-Vélez M, Berg WA. ACR BI-RADS® Ultrasound. In: ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology; 2013.
American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8ª ed. Nova York: Springer; 2017.
Trufelli DC, Miranda V da C, Santos MB, Fraile NM, Pecoroni PG, Gonzaga S de F, et al. Análise do atraso no diagnóstico e tratamento do câncer de mama em um hospital público. Rev Assoc Med Bras. 2008;54(1):72-6. http://dx.doi.org/10.1590/S0104-42302008000100024
Souza VO, Grando JPS, Couto Filho JO. Tempo decorrido entre o diagnóstico de câncer de mama e o início do tratamento, em pacientes atendidas no Instituto de Câncer de Londrina [Internet]. 2007 [acessado em 29 nov. 2017]. Disponível em: http://www.moreirajr.com.br/revistas.asp?fase=r003&id_materia=3763
Ramirez AJ, Westcombe AM, Burgess CC, Sutton S, Littlejohns P, Richards MA. Factors predicting delayed presentation of symptomatic breast cancer: a systematic review. Lancet. 1999;353(9159):1127-31.
Olivotto IA, Gomi A, Bancej C, Brisson J, Tonita J, Kan L, et al. Influence of delay to diagnosis on prognostic indicators of screen-detected breast carcinoma. Cancer. 2002;94(8):2143-50. https://doi.org/10.1002/cncr.10453
Huo Q, Cai C, Zhang Y, Kong X, Jiang L, Ma T, et al. Delay in Diagnosis and Treatment of Symptomatic Breast Cancer in China. Ann Surg Oncol. 2014;22(3):883-8. https://doi.org/10.1245/s10434-014-4076-9
Yu KD, Fan L, Qiu LX, Ling H, Jiang YZ, Shao ZM. Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent. Oncotarget. 2017;8(28):46549-56. https://doi.org/10.18632/oncotarget.10551
Desch CE, McNiff KK, Schneider EC, Schrag D, McClure J, Lepisto E, et al. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol. 2008;26(21):3631-7. https://doi.org/10.1200/JCO.2008.16.5068
Trufelli DC, Matos LL, Santi PX, Del Giglio A. Adjuvant treatment delay in breast cancer patients. Rev Assoc Med Bras. 2015;61(5):411-6.
Taplin SH, Weaver S, Salas E, Chollette V, Edwards HM, Bruinooge SS, et al. Reviewing cancer care team effectiveness. J Oncol Pract. 2015;11(3):239-46. https://doi.org/10.1200/JOP.2014.003350
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Alessandra Formigheri, Janaina Brollo, Fernando Vivian, Rafael Maciel Grochot, Solange de Cassia Pezzi Copatti, André Borba Reiriz, José Mauro Madi, Maximiliano Cassilha Kneubil
This work is licensed under a Creative Commons Attribution 4.0 International License.
